Scarica l'app Stockscreener
55.83
1.55%
0.8318
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BMY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Bristol Myers Squibb Co Borsa (BMY) Ultime notizie
Revisiting Stock Picks Intel, Progressive, Bristol Myers Squibb -- Barrons.com - Moomoo
Bristol Myers Follows Novartis, Sues Arkansas Over Pharmacy Law - Bloomberg Law News
Bristol Myers Squibb sets next earnings date, shares trade steadily on NYSE - Ad-hoc-news.de
Opdivo from Bristol-Myers Squibb Co.immunotherapy mainstay with new combo data - Ad-hoc-news.de
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Bristol-Myers Squibb Company (BMY) and SystImmune Announce Results from Analyses of Iza-bren Studies - Insider Monkey
Bristol Myers Squibb weighs dividend reset, shares trade near recent lows - AD HOC NEWS
Questex’s PODD, the Premier Gathering for Drug Delivery Industry Leaders, Announces the 16th Annual Conference Agenda - GlobeNewswire Inc.
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
Bristol-Myers Squibb Company (BMY) Stock Analysis: Exploring the 16.81% Upside Potential for Investors - DirectorsTalk Interviews
Why is Barclays Bullish on Bristol-Myers Squibb (BMY) Now - Kavout | AI
Bristol-Myers Squibb StockLong-term pipeline and business model under review - AD HOC NEWS
Bristol Myers Squibb Co. stock outperforms competitors despite losses on the day - MarketWatch
Bristol-Myers Squibb Co (CELG_r) Institutional Confidence - TradingKey
Bristol-Myers Squibb Co (CELG_r) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Bristol-Myers Squibb Co (CELG_r) Valuation: PE, PB & Fair Value Analysis - TradingKey
CHEMUNG CANAL TRUST CO's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol-Myers Squibb Co (CELG_r) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Bristol-Myers Squibb Company: Target Price Consensus and Analysts Recommendations | BMY | US1101221083 - marketscreener.com
Bristol-Myers Squibb (BMY) Maintains Quarterly Dividend at $0.63 per Share - GuruFocus
Bristol-Myers Squibb Co (CELG_r) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Faithward Advisors, LLC's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol-Myers Squibb Co (CELG_r) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Bristol Myers Squibb (BMY) Stock Could Be 12.2% Undervalued on Pipeline and Margin Hopes - Yahoo Finance
Measured Wealth Private Client Group, LLC's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol-Myers Squibb Co (BMY) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Bristol-Myers Squibb Co (BMY) Valuation: PE, PB & Fair Value Analysis - TradingKey
Bristol-Myers Squibb Co (CELG_r) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Bristol Myers Squibb declares $0.63 quarterly dividend - Investing.com
Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors - MarketWatch
Bristol Myers Squibb declares $0.63 quarterly dividend By Investing.com - Investing.com Canada
Bristol-Myers Squibb Co (CELG_r) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Bristol Myers Squibb Appoints Mayada Al-Ahmad as General Manager for Saudi Arabia & Gulf Countries - PR Newswire UK
BREYANZI® CAR T Cell Therapy Monitoring and Activity Updates Approved in Canada - PR Newswire Canada
Bristol-Myers Squibb Co (BMY) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Bristol-Myers Squibb Co (BMY) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Bristol-Myers Squibb Co (BMY) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Can BMY's Camzyos Strengthen Its Cardiovascular Portfolio? - Yahoo Finance
Bristol-Myers Squibb—ad spending, facts and profile - Ad Age
Psoriasis around the world - Bristol Myers Squibb
David Elkins - Bristol Myers Squibb
Bristol Myers Squibb (BMY) Stock Could Be 10.7% Undervalued After Kidney Cancer Trial Expansion - simplywall.st
Chris Boerner, Board Chair and Chief Executive Officer - Bristol Myers Squibb
Cari Gallman - Bristol Myers Squibb
Karin Shanahan - Bristol Myers Squibb
Technologies - Bristol Myers Squibb
BMY Faces Headline Risk Amid Medicare Drug Price Negotiation Pro - GuruFocus
A Dramatic Shift in Fed Policy Just Unlocked a New Era for Bristol Myers Squibb - Yahoo Finance
Panagora Asset Management Inc. Raises Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Squibb (BMY) Stock Analysis: Exploring a 10.41% Upside in the Healthcare Giant - DirectorsTalk Interviews
Bristol-Myers Squibb Stock (US1078421011): Dividend Safety Under the Microscope - AD HOC NEWS
How Safe is Bristol Myers Squibb's Dividend? Here's My Honest Take. - The Motley Fool
PIMCO RAE US Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Large Cap Core Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol Myers Squibb Company $BMY Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
Mike Kelly sells shares in Bristol-Myers Squibb and Comcast, buys Southeast Energy Authority bonds - Investing.com Canada
Can Bristol Myers' Growth Portfolio Offset Legacy Drug Declines? - Yahoo Finance
A Congress Member Sold Up To $65K In Bristol-Myers Squibb Stock: Here's What You Need To Know - Benzinga
Bristol Myers Squibb Company $BMY Stake Lifted by Xponance LLC - MarketBeat
ICICI Prudential Asset Management Co Ltd Sells 39,000 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb’s AI Overhaul And Oncology Trials Shape Value Story - Yahoo Finance
Why Bristol Myers Squibb (BMY) Outpaced the Stock Market Today - Yahoo Finance
Takeda’s Zasocitinib Beats BMS’s Sotyktu In Moderate-To-Severe Plaque Psoriasis - Citeline News & Insights
Takeda's AI-crafted psoriasis pill tops Bristol Myers' Sotyktu in head-to-head trial - Reuters
0.05%
0.24%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):